Dr. Reddy's receives USFDA approval for the launch of Capecitabine Tablets, USP

Dr. Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Feb 17, 2021 01:02 IST India Infoline News Service

Dr Reddys Laboratories
Dr. Reddy’s Laboratories Ltd. has announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health. Xeloda is a trademark of Hoffmann-La Roche Inc.

Dr. Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Dr Reddys Laboratories Ltd is currently trading at Rs4,583.40 apiece down by Rs112.60 or 2.40% from its previous closing of Rs4,696 apiece on the BSE.

Related Story

Open Free Demat Account (Rs699)